Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial. (2018)
Attributed to:
Low dose interleukin (IL)-2 in patients with a recent acute coronary syndrome
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.32117
Publication URI: https://www.repository.cam.ac.uk/handle/1810/284745
Type: Journal Article/Review